Completed PHASE2 INTERVENTIONAL 3-arm
NCT07212842
Methylene Blue-Enhanced Ultrafiltration Improves Outcomes After Cardiopulmonary Bypass
METHYLENE BLUE-ENHANCED BLOOD WASHING DURING ZERO-BALANCE ULTRAFILTRATION REDUCES FLUID OVERLOAD AND INFLAMMATORY RESPONSE FOLLOWING CARDIOPULMONARY BYPASS: A RANDOMIZED CLINICAL TRIAL
Sponsor: University of Sao Paulo
Conditions
Aortic Valve Surgery Cardiopulmonary Bypass Surgery Mitral Valve Surgery Myocardial Revascularization Surgery With Extracorporeal Circulation
Updated 1 time since 2025 Last updated: Oct 1, 2025 Started: Apr 12, 2021 Primary completion: Aug 25, 2023 Completion: Mar 16, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07212842, this PHASE2 trial focuses on Aortic Valve Surgery and Cardiopulmonary Bypass Surgery and remains completed. Sponsored by University of Sao Paulo, it has been updated 1 time since 2021, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
1 version recorded Completed — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- University of Sao Paulo
Data source: University of Sao Paulo
For direct contact, visit the study record on ClinicalTrials.gov .